SinuShunt – New disruptive medical device for treatment of hydrocephalus | SINUSHUNT | Proyecto | Ficha informativa | H2020 | CORDIS

Descripción del proyecto

Derivación innovadora para tratar la hidrocefalia

La hidrocefalia es una enfermedad grave asociada con la acumulación de líquido cefalorraquídeo (LCR) en el encéfalo. El tratamiento consiste en la implantación de un dispositivo de derivación en el tórax o el abdomen para drenar el LCR. El objetivo del proyecto SINUSHUNT, financiado con fondos europeos, es el desarrollo de un novedoso dispositivo médico implantable que drena el LCR en la vena sinusal, que es el lugar de reabsorción natural del LCR. El uso de una tecnología de endoprótesis innovadora supera los problemas de obstrucción asociados con las salidas convencionales y aumenta el tiempo de vida de la derivación, reduciendo la necesidad de volver a operar y otras complicaciones.

Objetivo

Hydrocephalus is a devastating neurological condition caused by accumulation of cerebrospinal fluid (CSF) on brain, and If left untreated, it can be fatal. The only treatment option is surgical, either implantation of a shunting device placed centrally in the brain, or, in some cases, by use of an endoscope going through the brain substance to its central part. The main problem in the industry is that conventional treatment systems (shunts) are based on a technology from 1950s and they are failing on average in 4-8 years, due to blockage or over-drainage. This results in 100 000 re-operations annually and brings a lot of complications (incl. increased infections) to the patient. Furthermore, this inefficiency represents an additional cost of €1.5B for the health care systems annually. To offer a solution to these problems, CSF-Dynamics is developing a new disruptive implantable medical device for treatment of hydrocephalus. The main innovation is draining the cerebrospinal fluid into sinus vein that is a natural resorption place of CSF, instead of conventional chest or abdomen. The hunt system uses novel stent technology as an outlet into the sinus vein, to avoid obstruction. SinuShunt competitive advantages are: 1) significantly increased life-time of the shunt, therefore reducing amount of re-operations; 2) Better quality of life for the patient due to the close to normal drainage of the brain-fluid, avoiding over-drainage and complications thereof. Hydrocephalus market is currently valued at €1.2B and is expected to reach a value of €1.6B by 2023. The market is steadily growing at CAGR of 4.4% during this time period. The market growth is propelled by growth in aging of population, increasing awareness of the condition and constantly improving diagnostic tools. Our end-users are hydrocephalus patients and users neurosurgeons. By 2026 we expect to sell our solution internationally, employ additional 112 people, and achieve a ROI of 40.6.